Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Memphasys Ltd ( (AU:MEM) ) has provided an announcement.
Memphasys Limited has notified the market of the issue of a total of 25 million unquoted Alignment Options in three tranches (6.5 million, 8.5 million and 10 million) on 19 December 2025. These options, which are not quoted and are not intended to be quoted on the ASX, form part of previously announced transactions and indicate the company’s continued use of equity-based instruments to align incentives and support its longer-term capital and remuneration strategies.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited is an ASX-listed company (code: MEM) operating in the biotechnology sector, with a focus on reproductive and fertility-related technologies and products. The company develops and commercialises solutions aimed at improving sperm quality and assisted reproductive procedures for global fertility markets.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.46M
See more insights into MEM stock on TipRanks’ Stock Analysis page.